Health insurance catalog adjustment: life-saving medicine please come in "zombie medicine" please go out.

Medicine Network September 21st, recently, the State Health Insurance Administration started the adjustment of the medical insurance catalogue, proposed that the new crown pneumonia-related respiratory disease treatment drugs, the second batch of state-organized drugs centralized procurement of selected drugs, and clinically urgently needed innovative drugs into the scope of the declaration.
At the same time, drugs assessed as risks outweighing benefits, "zombie drugs" in the catalogue, drugs that are generally de-listed internationally, exclusive drugs that can be replaced at high prices but have not been successfully negotiated, etc. will be transferred out of the catalogue to make room for good drugs of high clinical value.
according to the work programme, the current round of adjustments is divided into the preparation stage, the declaration stage, the expert review stage, the negotiation and bidding stage, and the announcement results stage.
is currently in the filing stage, while the much-watched bidding phase will take place from October to November.
this year's medical insurance drug catalog adjustment, will still comprehensively consider the functional positioning of basic medical insurance, clinical needs of drugs, fund affordability.
compared with previous rounds of catalog adjustment, the relevant person in charge of the National Health Insurance Administration pointed out that this year will be implemented in the national new coronary pneumonia diagnosis and treatment program of the off-catalog varieties into the scope of adjustment.
reporter learned that as of the end of July this year, medical insurance settlement of new crown pneumonia confirmed and suspected patients 173,000 times, settlement costs of about 1.8 billion yuan, of which 1.27 billion yuan of basic medical insurance expenditure.
, the cost of new coronary pneumonia testing will be included in the scope of health insurance payments for eligible patients.
said that the treatment of new crown pneumonia drugs into the scope of the declaration, will be practical action to support the prevention and control of the epidemic.
addition, drugs included in the 2018 edition of the list of essential drugs, included in the list of new drugs in urgent need of overseas clinical treatment, encouraged generic drugs or encouraged research and development to declare the list of children's drugs, etc., may be declared into the medical insurance catalogue.
, more and more innovative drugs have accelerated their influx into the market in recent years, according to the official.
from the perspective of health care, we hope to be able to bring valuable innovative drugs into health care as soon as possible.
But China's basic medical insurance financing is limited, in 2019 the per capita financing of residents' medical insurance is only about 800 yuan, two-thirds of which also comes from financial subsidies, we must adhere to the "basic" system positioning, the price is reasonable, high economic, to meet basic medical needs of drugs into the scope of the catalog.
note that in the past, the medical insurance catalog adjustment, drug access threshold generally as of the end of the previous year.
the first time this year, the programme was extended to 17 August, the date of its publication.
means that innovative drugs that have just been approved, particularly those with independent intellectual property rights, have faster access.
, the inclusion of eligible new drugs in the catalogue will also benefit the vast number of insured patients earlier.
The newly promulgated Interim Measures for the Administration of Basic Medical Insurance Drug Use eliminates the previous provision that "provincial medical insurance departments may add varieties on the basis of the national medical insurance catalogue, and the number of additions shall not exceed 15% of the total number of category B of the national catalogue", making it clear that the varieties that provincial health insurance departments may supplement are limited to ethnic medicines, medical institutions and Chinese medicine tablets.
understand that, at present, the National Health Insurance Administration is promoting the provinces to the original addition of drugs to digest.
In this catalog adjustment, the drugs that will enter the latest version of the list of basic medical insurance drugs at or above the provincial level will be included in the scope of adjustment, mainly considering that some provincial supplements may meet the criteria for inclusion in the national medical insurance drug catalogue.
the inclusion of these high clinically valuable, locally reimbursed drugs in the catalogue can guarantee the continuity and stability of the drug used by the patients involved.
the health care directory, the transfer will also be transferred out.
After comprehensive consideration, drugs assessed as risks outweighing benefits, "zombie drugs" in the catalogue, drugs that are generally de-listed internationally, exclusive drugs that can be replaced at high prices but have not been successfully negotiated, etc. will be transferred out of the catalogue to make room for good drugs of high clinical value.
.